TC E 202
Alternative Names: TC-E-202Latest Information Update: 02 Jan 2023
At a glance
- Originator TCRCure Biopharma
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cervical cancer
Most Recent Events
- 10 Aug 2022 Phase-I/II clinical trials in Cervical cancer (Refractory metastatic disease, Second-line therapy or greater) in China (Parenteral)
- 10 Aug 2022 Phase-I/II clinical trials in Cervical cancer (Refractory metastatic disease, Second-line therapy or greater) in China (Parenteral)(NCT05357027)
- 19 Nov 2021 The Center for Drug Evaluation of NMPA approves IND application for TC E202 in Cervical cancer